Seelos Therapeutics (NASDAQ:SEEL) & Allarity Therapeutics (NASDAQ:ALLR) Financial Analysis

Seelos Therapeutics (NASDAQ:SEEL) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Risk and Volatility

Seelos Therapeutics has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500. Comparatively, Allarity Therapeutics has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Seelos Therapeutics and Allarity Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seelos Therapeutics	0	2	1	0	2.33
Allarity Therapeutics	0	0	0	0	N/A

Seelos Therapeutics currently has a consensus target price of $240.00, indicating a potential upside of 105,163.16%. Given Seelos Therapeutics’ higher probable upside, analysts clearly believe Seelos Therapeutics is more favorable than Allarity Therapeutics.

Valuation & Earnings

This table compares Seelos Therapeutics and Allarity Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seelos Therapeutics	$2.20 million	0.23	-$37.88 million	N/A	N/A
Allarity Therapeutics	N/A	N/A	-$11.90 million	N/A	N/A

Allarity Therapeutics has lower revenue, but higher earnings than Seelos Therapeutics.

Institutional & Insider Ownership

23.4% of Seelos Therapeutics shares are held by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are held by institutional investors. 5.4% of Seelos Therapeutics shares are held by company insiders. Comparatively, 0.1% of Allarity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Seelos Therapeutics and Allarity Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seelos Therapeutics	203.13%	N/A	-431.47%
Allarity Therapeutics	N/A	-2,078.75%	-67.89%

Summary

Seelos Therapeutics beats Allarity Therapeutics on 8 of the 10 factors compared between the two stocks.

About Seelos Therapeutics

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.

About Allarity Therapeutics

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.